Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03282591 · ClinicalTrials.gov registry record · Phase 2
Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough
A Phase 2 study, sponsored by Vyne Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 185
- Enrollment target
NCT03282591: Completed Phase 2 study, sponsored by Vyne Therapeutics.
NCT03282591 is a Phase 2 study that has completed, run by Vyne Therapeutics. The registered enrollment target is 185 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (39% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03282591, a Phase 2 study, has completed, sponsored by Vyne Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 185 participants
- Enrollment target
Study Summary
Study of the efficacy, safety, and tolerability of serlopitant for the treatment of refractory chronic cough
Primary Outcome
Change in 24-hour objective cough frequency is total number of cough events during the monitoring period (24-hour interval)/24 (Total duration (in hours) for the monitoring period) which is captured through sound recordings by a custom-built digital recording device (VitaloJAK, Vitalograph, Ltd).
Interventions
- DRUG 5 mg Serlopitant Tablets
- DRUG Matching Placebo Tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 185 participants |
| Start Date | 2017-10-03 |
| Est. Completion | 2018-09-06 |
| Phase | Phase 2 |
What the finished NCT03282591 record still lists
NCT03282591 is an interventional study that assigns participants to a tested intervention. The registered 185 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (39% higher).
The record links to 0 conditions, and to 2 interventions - of which 5 mg Serlopitant Tablets is the first listed.
NCT03282591 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03282591 about?
NCT03282591 is a clinical study titled "Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough". Study of the efficacy, safety, and tolerability of serlopitant for the treatment of refractory chronic cough
What is the current status of trial NCT03282591?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 185 participants. The study started on 2017-10-03. Estimated completion is 2018-09-06.
What interventions are being tested in trial NCT03282591?
The interventions under investigation include: 5 mg Serlopitant Tablets (DRUG), Matching Placebo Tablets (DRUG).
Who is sponsoring clinical trial NCT03282591?
This trial is sponsored by Vyne Therapeutics, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03282591's enrollment target sits among peer trials
185 357th of 2000 higher than 1,641 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04041154 · 185 participants · NA
Behavioral and Neural Representations of Subjective Effort Cost
- NCT04484272 · 185 participants · NA
A Stress and Pain Self-management m-Health App for Adult Outpatients With Sickle Cell Disease
- NCT05020860 · 185 participants · Phase 2
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
- NCT05793541 · 185 participants · NA
Just-in-time Interventions for Reducing Short-term Suicide Risk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI